| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1c88da57ed94819c156a0fad624caa1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36134 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate |
2007-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54fd0bc56bb9dedec0c74ed1ee14526d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d256eabc772139629434c8314c4d805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cade8d7c6bc487036a11f0b1edc21b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91770fb42d3b22a383ac99e8fe2753cd |
| publicationDate |
2009-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2073839-A2 |
| titleOfInvention |
A vaccine for chikungunya virus infection |
| abstract |
The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus. |
| priorityDate |
2006-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |